Department of Psychiatry, Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, China.
Behav Brain Res. 2013 Sep 15;253:206-11. doi: 10.1016/j.bbr.2013.07.021. Epub 2013 Jul 19.
Quetiapine, an atypical antipsychotic, may have efficacy as augmentation therapy in treatment resistant depression (TRD), but evidence is limited and the underlying mechanism remains poorly understood. Therefore, this study was aimed to investigate whether and how quetiapine can be served as an augmentation agent in fluoxetine treatment resistant depressive rats induced by chronic unpredictable mild stress (CUMS). In this study, the effects of CUMS regimen and antidepressant treatment were assessed by behavioral tests and hippocampal neurogenesis. Approximately 20-30% of depressive rats respond poorly to fluoxetine treatment. In their hippocampus, a significant decrease of neurogenesis was also observed. However, quetiapine add-on therapy significantly improved the depressive behaviors and increased the number of the newborn neurons in the hippocampus of fluoxetine treatment resistant depressive rats. Thus, our results suggest that quetiapine may be used as an augmentation agent in the treatment resistant depression partly mediated by increasing the number of newborn neurons in the hippocampus.
喹硫平是一种非典型抗精神病药，可能对治疗抵抗性抑郁症（TRD）有疗效，但证据有限，其潜在机制仍知之甚少。因此，本研究旨在探讨喹硫平是否以及如何作为增效剂在慢性不可预测轻度应激（CUMS）诱导的氟西汀治疗抵抗性抑郁大鼠中发挥作用。在这项研究中，通过行为测试和海马神经发生来评估 CUMS 方案和抗抑郁治疗的效果。大约 20-30%的抑郁大鼠对氟西汀治疗反应不佳。在他们的海马体中，也观察到神经发生的显著减少。然而，喹硫平附加治疗显著改善了氟西汀治疗抵抗性抑郁大鼠的抑郁行为，并增加了海马中新神经元的数量。因此，我们的结果表明，喹硫平可能通过增加海马中新神经元的数量，作为治疗抵抗性抑郁症的增效剂。
